Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix cash
Cash and short-term investments held at the end of each period.
Renalytix's cash was $909.00K at Sep 30, 2024. For fiscal 2024 it was $4.68M, down 81.0% from the year before. The highest annual figure on record is $65.13M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $4.68M | -81.0% |
| FY2023 | Jun 30, 2023 | $24.68M | -40.3% |
| FY2022 | Jun 30, 2022 | $41.33M | -36.5% |
| FY2021 | Jun 30, 2021 | $65.13M | +356.2% |
| FY2020 | Jun 30, 2020 | $14.28M | +55.2% |
| FY2019 | Jun 30, 2019 | $9.20M | +11113.4% |
| FY2018 | Jun 30, 2018 | $82.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $909.00K | -93.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $4.68M | -81.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $4.70M | -85.8% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $5.62M | -76.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $13.89M | -55.2% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $24.68M | -40.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $33.03M | +2.1% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $23.82M | -40.4% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $31.04M | -52.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $41.33M | +189.5% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $32.36M | +251.9% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $39.93M | +48592.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $65.13M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $14.28M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $9.20M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $82.00K | – |
See a number that looks wrong?